scholarly journals Inflammatory Bowel Disease in Children of Middle Eastern Descent

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Christina Mai Ying Naidoo ◽  
Steven T. Leach ◽  
Andrew S. Day ◽  
Daniel A. Lemberg
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Middle Eastern ◽  
Control Group ◽  
Colonic Disease ◽  
Disease Course ◽  
Age And Gender ◽  
Inflammatory Bowel ◽  
And Gender ◽  
And Behavior

Increasing rates of inflammatory bowel disease (IBD) are now seen in populations where it was once uncommon. The pattern of IBD in children of Middle Eastern descent in Australia has never been reported. This study aimed to investigate the burden of IBD in children of Middle Eastern descent at the Sydney Children’s Hospital, Randwick (SCHR). The SCHR IBD database was used to identify patients of self-reported Middle Eastern ethnicity diagnosed between 1987 and 2011. Demographic, diagnosis, and management data was collected for all Middle Eastern children and an age and gender matched non-Middle Eastern IBD control group. Twenty-four patients of Middle Eastern descent were identified. Middle Eastern Crohn’s disease patients had higher disease activity at diagnosis, higher use of thiopurines, and less restricted colonic disease than controls. Although there were limitations with this dataset, we estimated a higher prevalence of IBD in Middle Eastern children and they had a different disease phenotype and behavior compared to the control group, with less disease restricted to the colon and likely a more active disease course.

scholarly journals Dental and periodontal disease in patients with inflammatory bowel disease

2021 ◽  
Author(s):  
Christopher X. W. Tan ◽  
Henk S. Brand ◽  
Bilgin Kalender ◽  
Nanne K. H. De Boer ◽  
Tymour Forouzanfar ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Periodontal Disease ◽  
Bowel Disease ◽  
Health Problems ◽  
Control Group ◽  
Age And Gender ◽  
Preventive Dental Care ◽  
Dmft Index ◽  
Inflammatory Bowel ◽  
And Gender

Abstract Objectives Although bowel symptoms are often predominant, inflammatory bowel disease (IBD) patients can have several oral manifestations. The aim of this study was to investigate the prevalence of dental caries and periodontal disease in patients with Crohn’s disease (CD) and ulcerative colitis (UC) compared to an age and gender-matched control group of patients without IBD. Material and methods The DMFT (Decayed, Missing, Filled Teeth) scores and the DPSI (Dutch Periodontal Screening Index) of 229 IBD patients were retrieved from the electronic health record patient database axiUm at the Academic Centre for Dentistry Amsterdam (ACTA) and were compared to the DMFT scores and DPSI from age and gender-matched non-IBD patients from the same database. Results The total DMFT index was significantly higher in the IBD group compared to the control group. When CD and UC were analyzed separately, a statistically significant increased DMFT index was observed in CD patients but not in UC patients. The DPSI did not differ significantly between the IBD and non-IBD groups for each of the sextants. However, in every sextant, IBD patients were more frequently edentulous compared to the control patients. Conclusion CD patients have significantly more dental health problems compared to a control group. Periodontal disease did not differ significantly between IBD and non-IBD groups as determined by the DPSI. Clinical relevance It is important that IBD patients and physicians are instructed about the correlation between their disease and oral health problems. Strict oral hygiene and preventive dental care such as more frequent checkups should be emphasized by dental clinicians.

scholarly journals P-029 Severity of Inflammatory Bowel Disease Hospitalizations Varies According to Age and Gender

2014 ◽  
Vol 20 ◽  
pp. S37-S38 ◽  
Author(s):  
Wuerth Brandon ◽  
Seminerio-Diehl Jennifer ◽  
Galandiuk Susan ◽  
Rockey Don
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Age And Gender ◽  
Inflammatory Bowel ◽  
And Gender

Diagnosis and Psychotherapeutic Needs by Freiburg Personality Inventory in Inflammatory Bowel Disease

2021 ◽  
Author(s):  
Cornelia Rada ◽  
Dan Gheonea ◽  
Denisa Elena Popa ◽  
Cristian George Tieranu
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Well Being ◽  
Personality Inventory ◽  
T Test ◽  
Somatic Complaints ◽  
Social Orientation ◽  
Control Group ◽  
Colonic Disease ◽  
Inflammatory Bowel

Abstract Background Despite recent discoveries in pharmacotherapy and psychotherapy, patients with inflammatory bowel disease (IBD) still face challenges with improvement, remission, and healing. The objectives of the study were to identify the characteristics of patients with IBD with the Freiburg Personality Inventory and the intensity of the colonic disease, comorbidities, and other factors that could be related to the personality of the subjects.Methods Data were collected in the period 2019–2020 from 46 patients from records at two hospitals. This study used nonparametric methods, such as the Wilcoxon-Mann–Whitney, Kolmogorov–Smirnov, Mann–Whitney U test, and BOOTSTRAP method. The control group was considered the national normative sample based on the average raw scores on the 12 personality assessment scales using the t test (one sample t test).Results Compared to the control group, the Inhibitedness, Health Concerns, and Emotionality scales had significantly higher raw scores. Additionally, the Social Orientation, Frankness, and Extraversion scales had significantly lower raw scores. Health status was a medical factor that influenced personality scales. On the Somatic Complaints scale, patients who had lesions or comorbidities had significantly higher raw scores. Patients who had comorbidities in addition to IBD had considerably higher raw scores on the Excitability scale.Conclusions Positive affective and cognitive adjustment interventions may aid people with IBD in managing life problems in a balanced manner while interpreting treatment outcomes with confidence. Psychotherapeutic change interventions regarding life perception are required to tackle the description of subjective suffering related to physical inconveniences (Somatic Complaints scale), a strong orientation toward performance (Strain scale), mood swings, anxiety, and pessimism (Emotionality scale). Another intervention is reconsidering values and (re)prioritization, such as family, intimate relationships, friends, health, growth, development, balanced work, all of which can promote a feeling of well-being and balance.

High Prevalence of Apical Periodontitis in Patients With Inflammatory Bowel Disease: An Age- and Gender- matched Case-control Study

2019 ◽  
Vol 26 (2) ◽  
pp. 273-279 ◽  
Author(s):  
Manuel Poyato-Borrego ◽  
Juan J Segura-Sampedro ◽  
Jenifer Martín-González ◽  
Yolanda Torres-Domínguez ◽  
Eugenio Velasco-Ortega ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Case Control Study ◽  
Case Control ◽  
Age And Gender ◽  
Inflammatory Bowel ◽  
Matched Case ◽  
And Gender ◽  
Matched Case Control Study ◽  
Control Study

Results of this age- and gender- matched case-control study show that the prevalence of apical periodontitis, diagnosed as radiolucent periapical lesions, is higher in patients with inflammatory bowel disease than in healthy control subjects (OR = 5.71; p = 0.0048).

scholarly journals Age and Gender: Affecting the Positive Rates of Serum PAB and ANCA in Patients with Inflammatory Bowel Disease

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Qingquan Chen ◽  
Shirong Huang ◽  
Yue Wu ◽  
Shuyu Zhang ◽  
Qicai Liu ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Young Male ◽  
Serum Levels ◽  
Immunofluorescence Assay ◽  
Age And Gender ◽  
Female Patients ◽  
Inflammatory Bowel ◽  
Male Patients ◽  
And Gender

Inflammatory bowel disease (IBD) is a group of immune-mediated conditions. Immune activity is varied by age and gender. The present study is aimed at investigating the effect of age and gender on the positive rates of anti-Saccharomyces cerevisiae antibodies (ASCA), anti-neutrophil cytoplasmic antibodies (ANCA), anti-intestinal goblet cell antibodies (GAB), and antibodies to exocrine pancreas (PAB) in IBD patients. A total of 1871 hospitalized patients with confirmed IBD were included in this study. Sera were obtained from each subject for antibody measurement by indirect immunofluorescence assay. The positive rates of ANCA IgG and IgA were higher in female patients than those in male patients ( P < 0.001 ) while the positive rate of PAB IgG was just reversed ( P < 0.001 ). Moreover, the median ages of patients with positive ANCA IgG and IgA were higher than patients with negative antibodies ( P = 0.0019 and P = 0.0110 , respectively), while the median ages of patients with positive PAB IgG and IgA were significantly lower than patients with negative PAB ( P < 0.0001 ). The serum levels of ANCA IgG and IgA were potentiated in old female patients, while serum PAB IgG was easy to be detected in the young male patients with IBD.

scholarly journals Predicting disease course in ulcerative colitis using stool proteins identified through an aptamer-based screen

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Sanam Soomro ◽  
Suresh Venkateswaran ◽  
Kamala Vanarsa ◽  
Marwa Kharboutli ◽  
Malavika Nidhi ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Fecal Calprotectin ◽  
Disease Monitoring ◽  
Disease Course ◽  
Lipocalin 2 ◽  
Time Points ◽  
Inflammatory Bowel ◽  
Stool Samples

AbstractIn the search for improved stool biomarkers for inflammatory bowel disease (IBD), an aptamer-based screen of 1129 stool proteins was conducted using stool samples from an IBD cohort. Here we report that of the 20 proteins subsequently validated by ELISA, stool Ferritin, Fibrinogen, Haptoglobin, Hemoglobin, Lipocalin-2, MMP-12, MMP-9, Myeloperoxidase, PGRP-S, Properdin, Resistin, Serpin A4, and TIMP-1 are significantly elevated in both ulcerative colitis (UC) and Crohn’s disease (CD) compared to controls. When tested in a longitudinal cohort of 50 UC patients at 4 time-points, fecal Fibrinogen, MMP-8, PGRP-S, and TIMP-2 show the strongest positive correlation with concurrent PUCAI and PGA scores and are superior to fecal calprotectin. Unlike fecal calprotectin, baseline stool Fibrinogen, MMP-12, PGRP-S, TIMP-1, and TIMP-2 can predict clinical remission at Week-4. Here we show that stool proteins identified using the comprehensive aptamer-based screen are superior to fecal calprotectin alone in disease monitoring and prediction in IBD.

scholarly journals GLP-1 based therapies and disease course of inflammatory bowel disease

2021 ◽  
pp. 100979
Author(s):  
Marie Villumsen ◽  
Astrid Blicher Schelde ◽  
Espen Jimenez-Solem ◽  
Tine Jess ◽  
Kristine Højgaard Allin
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Disease Course ◽  
Inflammatory Bowel

USTEKINUMAB FOR CHRONIC GRANULOMATOUS DISEASE-ASSOCIATED INFLAMMATORY BOWEL DISEASE

2021 ◽  
Vol 27 (Supplement_1) ◽  
pp. S59-S59
Author(s):  
Sumona Bhattacharya ◽  
Beatriz Marciano ◽  
Harry Malech ◽  
Steven Holland ◽  
Suk See De Ravin ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Chronic Granulomatous Disease ◽  
Bowel Disease ◽  
Clinical Remission ◽  
Colonic Disease ◽  
Cell Transplant ◽  
Granulomatous Disease ◽  
Efficacy And Safety ◽  
Serious Infections ◽  
Inflammatory Bowel

Abstract Introduction Chronic granulomatous disease (CGD) is a rare immunodeficiency caused by mutations in the NADPH oxidase complex. Dysregulated immune function may cause inflammatory bowel disease (IBD). Patients with CGD-associated IBD may not respond to or may develop serious infections as a result of traditional IBD therapies such as vedolizumab and infliximab. Ustekinumab is approved for use in Crohn’s disease and ulcerative colitis however there is scarce data on its efficacy and safety in CGD. Aims To evaluate the efficacy and safety of ustekinumab for CGD-associated IBD. Methods A retrospective chart review was conducted on CGD patients followed at a single center who had consented to participate in a natural history study. Clinical, laboratory, and endoscopic data were extracted in those that had received ustekinumab for IBD. Results Eight patients were found. Four were male and four were female. Five were white, one was Asian, one was black, and one was mixed race. Median age at diagnosis of CGD was 3 years (IQR 8) and of IBD was 15.5 years (IQR 20). Median age at initiation of ustekinumab was 27.5 years (IQR 14) and median duration on ustekinumab was 10 months (IQR 7). Six had colonic disease, two had ileocolonic disease, and six had perianal disease. Six failed other biologics (n=5 for vedolizumab, n=1 for infliximab, n=1 for adalimumab). Six patients symptomatically improved whereas two had no improvement. Changes in hemoglobin and C-reactive protein were equivocal. Three patients had improved endoscopic findings, two had unimproved findings, and three patients lacked this data. Overall, four patients achieved clinical remission. However, none of the five patients with endoscopic reevaluation achieved endoscopic remission. Three patients discontinued therapy due to lack of response: two required surgery and one underwent stem cell transplant. Fungal pneumonia (n=2), otitis media (n=1), oral herpes simplex virus 1 (n=1), and viral gastroenteritis (n=1) were reported. One infusion reaction occurred. Discussion In our cohort of eight patients with CGD-associated IBD receiving ustekinumab, results were mixed with four patients experiencing some degree of clinical or endoscopic improvement including four who achieved clinical remission. Multiple CGD-related variables may account for the mixed laboratory findings. Four of the five patients with endoscopic reevaluation had pre-existing strictures that would be unlikely to reverse with medical therapy alone. Of these, two had otherwise resolved endoscopic inflammation. Only two patients had no endoscopic improvement. Two serious infections occurred however CGD confers increased infectious susceptibility and no infections lead to discontinuation of therapy. Given these promising results, further formalized study of ustekinumab in CGD-associated IBD is needed.

scholarly journals Sa1248 Late Adult-Onset Inflammatory Bowel Disease Patients Require Surgery Earlier During Their Disease Course Compared to Early Adult-Onset Patients

2012 ◽  
Vol 142 (5) ◽  
pp. S-253-S-254 ◽  
Author(s):  
Christina Y. Ha ◽  
Theodore M. Bayless ◽  
Alain Bitton ◽  
Judy H. Cho ◽  
Richard H. Duerr ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Disease Course ◽  
Adult Onset ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document